Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer
To investigate the efficacy and safety of Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR+/HER2+ Metastatic Breast Cancer
Breast Cancer
DRUG: Dalpiciclib|DRUG: Fulvestrant|DRUG: Pertuzumab|DRUG: Trastuzumab
Progression-Free Survival (PFS), Progression free survival, 6 weeks
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, Safety, 6 weeks|Objective response rate (ORR), Proportion of subjects whose efficacy was evaluated as Complete Response(CR)/PR, 6 weeks|Clinical benefit rate (CBR), Proportion of subjects with CR, PR and SD≥24 weeks during the study, 6 weeks|Duration of remission (DoR), The time from the first assessment of CR or PR to the first assessment of Progressive Disease(PD) or death from any cause；, 6 weeks|Overall Survival (OS), 6 weeks
To investigate the efficacy and safety of Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR+/HER2+ Metastatic Breast Cancer